Therefore, JAK1/JAK2 inhibition is shown to be a potential tool for improving health outcomes in patients inhibiting hyperglycemia-induced damage to kidney cells, improving renal function, reducing renal inflammation and fibrotic lesions and slowing the progression of DKD (Chen et al., 2021). Here, JAK1 is linked to diabetic kidney disease.